Our mission is to unite and align key diabetes stakeholders and the larger diabetes community around key
diabetes-related policy and legislative efforts in order to elevate diabetes on the national agenda.

Detection

DAA’s 2018 Advocacy Priorities. Screening for diabetes is a policy priority for the Diabetes Advocacy Alliance (DAA) because screening is the entry point for detection of prediabetes, type 2 diabetes, and gestational diabetes. (Click here for a complete list of the DAA’s 2018 Advocacy Priorities.) With screening, we can:

  • Identify adults with prediabetes, who could benefit from diabetes prevention programs.
  • Identify adults with undiagnosed diabetes, enabling them to begin treatment and care to help prevent the serious health complications of diabetes.
  • Identify women with gestational diabetes, to connect them with appropriate treatment and care for themselves and their baby.




Screening
Improving screening rates and reducing the number of people with undiagnosed prediabetes, type 2 diabetes, and gestational diabetes is paramount in our effort to change the trajectory of the diabetes epidemic in the United States. Of particular interest, in October 2015 the U.S. Preventive Services Task Force (USPSTF) released a final guideline on screening for abnormal blood glucose and type 2 diabetes. The guideline recommends screening in adults aged 40 to 70 years who are overweight or obese, among other risk factors, and says clinicians should offer or refer patients with abnormal glucose to intensive behavioral lifestyle interventions. Under the ACA, private health insurers are required to cover the screening and participation in diabetes prevention programs at no cost to the patient. Disseminating information and helping to implement this final guideline is a priority.

To view more on DAA’s work to improve screening rates, click here.